Smith Kline & French Laboratories Limited

Smithkline Beckman Corporation

John C Emmett

Graham J Durant

Charon R Ganellin

Hunter Douglas Prain

Thomas H Brown

Paul D Leeson

Robert A Slater

James Whyte Black

David Ellis

Anthony H Underwood

William J Coates

Brian H Warrington

Charon R Genellin

Charo R Ganellin

Charon F Ganellin

This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3)1H)-pyridazinylmethyl)-thyronine.

Benzyl pyridyl and pyridazinyl compounds

The invention relates to 2-aminopyrimidinone derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(1,4-dihydro-4-oxo-2-pyrimidinylamino)phenyl]-5-methyl-4,5-dihydro-3( 2H)-pyridazinone.

Pyridazinone derivatives

The invention relates to phenyl dihydropyridazinone derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(N.sup.3 -benzyl-N.sup.2 -cyanoguanidino)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone.

Novel guanidino pyridazinones as cardiac stimulants

This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine.

Pyridyl and pyridazinyl substituted thyronine compounds

This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinyl-methyl]-thyronine.

Chemical compounds having selective thyromimetic activity

Pyridyl and pyridazinyl substituted thyronine compounds having selective

This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds has inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.

Heterocyclic compounds having inotropic activity

This invention relates to 5-(4-substituted)phenylpyrazinone compounds which have positive inotropic and vasodilator activity. One such compound is 5-(4-carboxamidophenyl)pyrazin-2(1H)-one.

5-(4-substituted)phenyl-2-pyrazinones

Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolymethylthio)ethylamino]-4-pyrimidone.

Pharmacologically active compounds

Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamino]-4-pyrimidone.

Heterocyclic alkylaminoheterocycles

This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds have inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.

5-(4-Amino or acylaminophenyl)-2(1H)-pyrazinones having inotropic

Heterocyclic alkyl(or methylthioalkyl)amino-1,2,4-triazine compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors.

Growing community of inventors

Codicote, United Kingdom

John C Emmett